ANDA 72162, held by Heritage Pharma. Maprotiline Hydrochloride.
As of Nov 16, 2026, ANDA 72162 (Maprotiline Hydrochloride), held by Heritage Pharma, was first approved by FDA on Jun 1, 1988, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 1988 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Maprotiline Hydrochloride25MG · tablet;oral | Maprotiline Hydrochloride | Discontinued |
| Jul 17, 2014 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 7, 2002 | Supplement 8Manufacturing | Approved | None posted |
| Nov 10, 1999 | Supplement 7Manufacturing | Approved | None posted |
| Aug 26, 1998 | Supplement 6Labeling | Approved | None posted |
| Jun 4, 1992 | Supplement 5Labeling | Approved | None posted |
| May 20, 1992 | Supplement 4Labeling | Approved | None posted |
| Jan 18, 1991 | Supplement 3Labeling | Approved | None posted |
| Apr 26, 1989 | Supplement 2Bioequivalence | Approved | None posted |
| Jun 1, 1988 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters